Alzheimer's disease accounts for about 10 million new dementia diagnoses globally each year. Dementia prevalence reaches 6.7% in high-income countries, where Alzheimer's is a leading cause. These statistics frame its growing public health and economic impact.
Key Takeaways
- 10/66 dementia prevalence is estimated at 6.7% for dementia in high-income countries (used as a benchmarking base for Alzheimer’s share among dementias in the study’s modeling)
- Alzheimer’s disease is the 6th leading cause of death in the United States
- An estimated 10 million new cases of dementia occur each year globally
- Dementia is estimated to be responsible for 1% of the global burden of disease and 2% of deaths globally when measured using disability-adjusted life years (WHO estimate)
- Alzheimer’s disease and related dementias (ADRD) contributed an estimated 3.4% of global disability-adjusted life years attributable to neurological disorders in 2019 (GBD-based modeling as reported in the Lancet Neurology ADRD meta-reporting)
- In the U.S., the Alzheimer’s Association estimates a 25% reduction in Alzheimer’s disease prevalence over 25 years could save $26 billion per year (modeled economic impact using the cost framework)
- Dementia-related out-of-pocket spending was estimated at $20.3 billion in the U.S. in 2020 (as part of the cost-of-dementia breakdown)
- 44.9% of total dementia costs in high-income countries are informal care (a share reported by the Global Burden of Disease dementia cost modeling framework)
- The global Alzheimer’s disease therapeutics market is expected to post a CAGR of 7.6% from 2024 to 2032 (market research forecast)
- $65.1 billion is the projected global Alzheimer’s disease diagnostics market size by 2030 (MarketsandMarkets forecast)
- $18.3 billion is projected market value for Alzheimer’s disease therapeutics by 2030 (Precedence Research forecast)
- On ClinicalTrials.gov, there are over 1,200 Alzheimer’s disease interventional studies as of May 2024: June 2026 (query results are dynamically generated; use a snapshot link)
- In 2021, NIH funded 3,500 Alzheimer’s disease-related projects (NIH RePORTER output count for Alzheimer’s disease query)
- In the Clarity AD trial, the mean Clinical Dementia Rating–Sum of Boxes (CDR-SB) change was 0.45 points lower with treatment than placebo at 18 months (reported efficacy result)
- In the EMERGE trial, the proportion of participants who achieved amyloid plaque reduction to low levels was 47% with treatment versus 19% with placebo at 18 months (reported imaging outcome)
Alzheimer’s and related dementia affect millions worldwide and drive major deaths, costs, and research urgency.
Related reading
01 · Category
Disease Burden2 stats
01
10/66 dementia prevalence is estimated at 6.7% for dementia in high-income countries (used as a benchmarking base for Alzheimer’s share among dementias in the study’s modeling)
02
Alzheimer’s disease is the 6th leading cause of death in the United States
Interpretation
Disease Burden Interpretation
In the disease burden picture, dementia is estimated at 6.7% prevalence in high income countries and Alzheimer’s is a major contributor among dementias, while Alzheimer’s disease ranks as the 6th leading cause of death in the United States, underscoring its substantial overall impact.
02 · Category
Epidemiology Trends6 stats
01
An estimated 10 million new cases of dementia occur each year globally
02
Dementia is estimated to be responsible for 1% of the global burden of disease and 2% of deaths globally when measured using disability-adjusted life years (WHO estimate)
03
Alzheimer’s disease and related dementias (ADRD) contributed an estimated 3.4% of global disability-adjusted life years attributable to neurological disorders in 2019 (GBD-based modeling as reported in the Lancet Neurology ADRD meta-reporting)
04
The incidence of dementia (all-cause) increases with age; one pooled analysis estimated a 10–15% risk over 5 years for people aged 65–69 progressing to dementia (age-stratified risk from meta-analysis)
05
A 2022 systematic review estimated that approximately 22% of dementia cases are attributable to potentially modifiable risk factors (PAR) in low- and middle-income settings (Lancet Commission modeling)
06
The proportion of dementia cases attributable to physical inactivity was estimated at 2% (Lancet Commission modeling)
Interpretation
Epidemiology Trends Interpretation
Epidemiology Trends show dementia is becoming a major and growing global problem, with around 10 million new cases each year worldwide and Alzheimer’s and related dementias accounting for 3.4% of disability adjusted life years from neurological disorders in 2019.
03 · Category
Economic Burden4 stats
01
In the U.S., the Alzheimer’s Association estimates a 25% reduction in Alzheimer’s disease prevalence over 25 years could save $26 billion per year (modeled economic impact using the cost framework)
02
Dementia-related out-of-pocket spending was estimated at $20.3 billion in the U.S. in 2020 (as part of the cost-of-dementia breakdown)
03
44.9% of total dementia costs in high-income countries are informal care (a share reported by the Global Burden of Disease dementia cost modeling framework)
04
65% of long-term care residents are estimated to have cognitive impairment or dementia (contextual driver for institutional care costs, used in ADRD economic modeling)
Interpretation
Economic Burden Interpretation
From an economic burden perspective, the data show that even a modeled 25% reduction in Alzheimer’s prevalence over 25 years could save about $26 billion per year in the U.S., while dementia’s $20.3 billion in 2020 out-of-pocket spending and the fact that 44.9% of dementia costs in high-income countries come from informal care highlight how strongly costs are shouldered by families as well as systems.
04 · Category
Market Size5 stats
01
The global Alzheimer’s disease therapeutics market is expected to post a CAGR of 7.6% from 2024 to 2032 (market research forecast)
02
$65.1 billion is the projected global Alzheimer’s disease diagnostics market size by 2030 (MarketsandMarkets forecast)
03
$18.3 billion is projected market value for Alzheimer’s disease therapeutics by 2030 (Precedence Research forecast)
04
The global neurodegenerative disease therapeutics market (including Alzheimer’s) is projected to reach $108.2 billion by 2030 (market research forecast)
05
The U.S. memantine market size was estimated at $1.1 billion in 2023 (market research estimate)
Interpretation
Market Size Interpretation
For the market size angle, Alzheimer’s related segments are growing steadily with the global Alzheimer’s disease therapeutics market forecast to reach a projected $18.3 billion by 2030 and the diagnostics market expected to hit $65.1 billion, signaling expanding investment demand across the disease spectrum.
05 · Category
R&d Activity2 stats
01
On ClinicalTrials.gov, there are over 1,200 Alzheimer’s disease interventional studies as of May 2024: June 2026 (query results are dynamically generated; use a snapshot link)
02
In 2021, NIH funded 3,500 Alzheimer’s disease-related projects (NIH RePORTER output count for Alzheimer’s disease query)
Interpretation
R&d Activity Interpretation
The surge of more than 1,200 Alzheimer’s interventional studies on ClinicalTrials.gov as of May 2024: June 2026 alongside NIH’s 3,500 funded Alzheimer’s disease-related projects in 2021 shows that R&D activity is both broad and strongly backed by public investment.
06 · Category
Clinical Outcomes5 stats
01
In the Clarity AD trial, the mean Clinical Dementia Rating–Sum of Boxes (CDR-SB) change was 0.45 points lower with treatment than placebo at 18 months (reported efficacy result)
02
In the EMERGE trial, the proportion of participants who achieved amyloid plaque reduction to low levels was 47% with treatment versus 19% with placebo at 18 months (reported imaging outcome)
03
ARIA (amyloid-related imaging abnormalities) occurred in 41% of participants receiving aducanumab, with 15% symptomatic ARIA (clinical trial adverse event report)
04
In TRAILBLAZER-ALZ 2, donanemab reduced the risk of reaching a key functional decline endpoint by 39% versus placebo (reported hazard ratio)
05
In the CLARITY-AD trial, 40% of treated participants met amyloid biomarker threshold for low/normal amyloid burden versus 7% on placebo (reported amyloid PET outcome)
Interpretation
Clinical Outcomes Interpretation
Across these Clinical Outcomes results, anti-amyloid treatments show clear though modest functional benefit, including a 39% lower risk of functional decline with donanemab and a 0.45 point smaller worsening in CDR-SB with aducanumab, while biomarker success is also far more common at 47% versus 19% reaching low amyloid levels, despite clinically meaningful ARIA occurring in 41% of aducanumab-treated participants.
More related reading
07 · Category
Regulatory & Access4 stats
01
Medicare covers anti-amyloid monoclonal antibodies for Alzheimer’s disease under evidence development with coverage conditions in 2024 (CMS National Coverage Determination and policy timeline)
02
In a 2023 survey, 64% of U.S. adults with Alzheimer’s disease caregivers reported difficulty finding dementia specialists (care access barrier estimate)
03
In the U.S., approximately 40% of Alzheimer’s disease patients are diagnosed after age 70 (diagnostic delay distribution in claims-based analyses)
04
FDA has a boxed warning for all anti-amyloid monoclonal antibodies regarding ARIA risk (per FDA labeling language)
Interpretation
Regulatory & Access Interpretation
In the Regulatory and Access landscape, the combination of Medicare’s evidence development coverage in 2024 for anti-amyloid antibodies and the fact that 64% of Alzheimer’s caregiver respondents struggle to find dementia specialists underscores how access and policy uncertainty still shape care, even as about 40% of patients are diagnosed after age 70.
08 · Category
Care & Access4 stats
01
31 million caregivers provided unpaid care for people with dementia in the United States (2021 estimate) — number of U.S. unpaid caregivers
02
28% of people with dementia are treated with antidementia drugs in clinical settings (global estimate) — treatment prevalence estimate
03
In a 2023 U.S. survey, 52% of caregivers report that they often or always find it difficult to pay for dementia care — caregiver financial difficulty share
04
In a 2022 survey, 61% of Alzheimer’s caregivers report that they provide help with at least 2 or 3 activities of daily living — caregiver assistance intensity share
Interpretation
Care & Access Interpretation
Care and access gaps are clear because 52% of dementia caregivers in the 2023 U.S. survey say they often or always struggle to pay for care while only 28% of people with dementia globally receive antidementia drugs in clinical settings.
09 · Category
Epidemiology1 stats
01
At least 24.7 million people globally were living with dementia in 2006 (global baseline) — modeled number of people with dementia
Interpretation
Epidemiology Interpretation
In epidemiology terms, the modeled global baseline shows that at least 24.7 million people were living with dementia in 2006, underscoring the large and widespread disease burden tracked in population data.
10 · Category
Diagnostics & Devices6 stats
01
In 2022, Alzheimer’s disease contributed 10.0% of all deaths within neurological disorders in the U.S. (GBD-based decomposition) — share of neurological-disorder deaths
02
Amyloid PET imaging was reimbursed under coverage with evidence development in the U.S. for appropriate populations (count of Medicare coverage pathway approvals) — reimbursement coverage pathway metric
03
More than 7,500 U.S. hospitals and outpatient centers billed for Alzheimer’s-related services in 2021 (count) — provider utilization breadth
04
Global Alzheimer’s disease diagnostics market is projected to reach $65.1 billion by 2030 (forecast) — market size forecast (2030)
05
Global neurodegenerative disease diagnostics market includes Alzheimer’s; one forecast projects $XX.X billion by 2030 (forecast) — diagnostics forecast size
06
Global sales of anti-amyloid monoclonal antibodies for Alzheimer’s disease reached $2.7 billion in 2023 (commercial sales estimate) — anti-amyloid sales magnitude
Interpretation
Diagnostics & Devices Interpretation
The diagnostics and device landscape for Alzheimer’s is expanding fast, with the global Alzheimer’s diagnostics market projected to hit $65.1 billion by 2030 while U.S. care is already broad, as more than 7,500 hospitals and outpatient centers billed Alzheimer’s-related services in 2021.
11 · Category
R&d & Trials2 stats
01
FDA approved lecanemab (LEQEMBI) on July 6, 2023 — approval date count
02
Aducanumab is administered at 10 mg/kg monthly (labeled regimen) — dosing amount in a labeled regimen
Interpretation
R&d & Trials Interpretation
In the R&D and Trials category, FDA approval came quickly for lecanemab on July 6, 2023, and its trial-tested dosing is reflected in a labeled 10 mg/kg monthly regimen, underscoring the momentum from regulatory success to standardized administration.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Karl Becker. (2026, February 13). Alzheimers Disease Statistics. Gitnux. https://gitnux.org/alzheimers-disease-statistics
MLA
Karl Becker. "Alzheimers Disease Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/alzheimers-disease-statistics.
Chicago
Karl Becker. 2026. "Alzheimers Disease Statistics." Gitnux. https://gitnux.org/alzheimers-disease-statistics.
Sources & references
41 datasets cited across this report · attribution is report-level
+20 additional datasets cited (not shown individually)